ALX Onconology Holdings Inc

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company's predecessor was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in Burlingame, CA.

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the Company will be presenting early clinical data from ASPEN-02, its ongoing Phase 1/2 study evaluating evorpacept in combination with azacitidine for the treatment of myelodysplastic syndromes (“MDS”) in a poster presentation at the 63rd American Society of Hematology (“ASH”) Annual Meeting held December 11-14, 2021 in Atlanta, Georgia.

ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in four upcoming virtual investor conferences.

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company, and ScalmiBio, Inc. (“ScalmiBio”) announced today that ALX Oncology has acquired ScalmiBio.

ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio

Zymeworks Inc

VANCOUVER, British Columbia & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in an open-label, multi-center Phase 1b/2 clinical trial conducted by Zymeworks. The trial is designed to eva

Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors

-- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center -- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center

ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma

With recent buyouts of Trillium Therapeutics and Forty Seven Inc. in the CD47 space, it's my belief that should ALX Oncology deliver on data it could be next. ALX's CD47 drug ALX148 (Evorpacept) has shown great early clinical evidence in a few studies, and the drug already has seen interest from both Merck and Eli Lilly.

ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space

Beam Therapeutics

Vertex Pharmaceuticals

Let your portfolio reflect your personality.

The 3 Best Biotech Stocks to Buy Right Now

ALX Oncology Holdings Inc (NASDAQ: ALXO) shares are trading higher by 19.3% at $74.69, potentially in sympathy with Trillium Therapeutics which announced an acquisition by Pfizer Monday. ALX Oncology is a clinical-stage immuno-oncology company.

So What's Going On With ALX Oncology's Stock?

The shares of ALX Oncology Holdings Inc (NASDAQ: ALXO) increased by over 25% pre-market. This is why it happened.

ALX Oncology Shares Increase Over 25% Pre-Market: Why It Happened

BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June 30, 2021 and provided clinical development and operational highlights.

ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated

ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

ALX Oncology Holdings Inc. (ALXO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ALX Oncology Holdings Inc. (ALXO) Upgraded to Buy: Here's What You Should Know

ALX Oncology (ALXO) has been struggling lately, but the selling pressure may be coming to an end soon.

ALX Oncology (ALXO) Sees Hammer Chart Pattern: Time to Buy?

Advaxis

Odonate Therapeutics

Provention Bio Inc

Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the biggest biopharma movers Tuesday. Odonate Gains On Institutional Stake: Shares of Odonate, a biopharma which recently announced discontinuation of development of an oral chemotherapy candidate named tesetaxel, are seeing renewed buying following disclosure of institutional stake.

Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today

ALX Oncology Holdings Inc (NASDAQ: ALXO) announced updated data from its ongoing ASPEN-01 Phase 1b trial evaluating ALX148 in combination with trastuzumab and chemotherapy to treat gastric or gastroesophageal junction cancer (GC). The new data were shared at the World Congress on Gastrointestinal Cancer.

ALX Oncology Shares Jump As ALX148 Shows ORR of 72% In Patients With HER2 Positive Stomach Cancer

-- ORR of 72% Observed in Patients with > 2L HER2 Positive Gastric or Gastroesophageal Junction Cancer  -- Estimated OS at 12 months of 76%  -- ALX Oncology to Host Conference Call on July 6 th at 8:30 a.m. ET

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

--Interim report completed by ALX for a standard ongoing non-clinical safety study

ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies

Randomized Phase 2/3 Study is Planned Based on Promising Results from the ASPEN-01 Phase 1b Trial in Gastric Cancer Patients Randomized Phase 2/3 Study is Planned Based on Promising Results from the ASPEN-01 Phase 1b Trial in Gastric Cancer Patients

ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer

BURLINGAME, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2021 and provided recent clinical development and operational highlights.

ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

- The first of two distinct randomized Phase 2 studies in collaboration with Merck  has been initiated

ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

Alx Oncology Holding sees its Relative Strength Rating enter the 80-plus level. The post Alx Oncology Holding Meets 80-Plus Relative Strength Rating Benchmark appeared first on Investor's Business Daily.

Alx Oncology Holding Meets 80-Plus Relative Strength Rating Benchmark

Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancer Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancer

ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer

BURLINGAME, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announces that the post-grant review period for granted U.S. Patent No. 10,696,730 ended on March 30, 2021. This patent covers the lead product candidate ALX148, a next generation CD47-blocking therapeutic that combines a high-affinity signal regulatory protein-alpha (“SIRP“) CD47-binding domain fused with an inactivated, proprietary Fc domain. The U.S. patent is not expected to expire before August 5, 2036, excluding patent term adjustments or extensions.

ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148

Alcon Inc. - Registered Shares

CuriosityStream

Semtech

Upstart Holdings

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Alcon, Semtech, Upstart, and others.

Top Wall Street analysts bet on these stocks for long-term growth

BURLINGAME, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided clinical development and operational highlights.

ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

News for ALX Onconology Holdings Inc Stock (ALXO)